The Effect of Capecitabine and Cisplatin as a Radiosensitizer in Radiation of Bladder Cancer

Assessment of Tolerability, Response and Complications of Capecitabin added to Cisplatine for Concurrent Chemoradiation of Muscle Invasive Bladder Cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180815040801N1

Enrollment

Registered

2019-02-06

Start date

2018-01-20

Completion date

Unknown

Last updated

2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder cancer. Malignant neoplasm of bladder, unspecified

Interventions

Intervention group: Patients with muscle invasive bladder cancer at T2-T4aN0M0 stage referring to Department of Radiation Oncology Cancer Institute.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with muscle invasive bladder cancer (T2 to T4a) TCC pathology Patient's refusal of radical cystectomy or not being candidate to do that due to medical comorbidities Referred by an urologist for concurrent chemoradiation of bladder cancer

Exclusion criteria

Exclusion criteria: Hydronephrosis that does not resolve with usual treatments Lymphatic or distant metastasis Cr>2 GFR <30 WBC<3000 PLT<80,000

Design outcomes

Primary

Measure	Time frame
The amount of treatment tolerability and completion in adding capecitabine to cisplatin in comoradiation of muscle invasive bladder cancer. Timepoint: Weekly during treatment and three months after termination of the treatment. Method of measurement: CTCAE 4.03 2010 (Common Terminology Criteria for Adverse Events).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSara Soltanzadeh

Tehran University of Medical Sciences

sara.soltanzadeh@gmail.com+98 21 6119 2567

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026